"Including
evidence-based decision-making in the healthcare coverage process would
ensure that use of new therapy and technology is tied to evidence of
clinical benefit, resulting in a value-based health care system."
Rita Redberg, MD. Health
Affairs,
February 2007 |
275
Middlefield Road
Suite 200
Menlo
Park, CA
94025
Tel:
650.327.2085
Fax:
650.327.1506
Email: info@cedarecon.com
|
Cedar
Associates LLC provides
life
sciences
organizations and companies with scientifically reliable and credible
evidence on clinical outcomes and economics of services and
technologies. We use state-of-the-art analytical techniques and seek to
present our findings in a manner that is readily understood by a
diverse audience, such as physicians, patients, managers, and
third-party payers and decision-makers.
We
have
close collaborations with numerous international renowned
experts at local, regional and national institutions (e.g., Stanford
University,
UC Berkeley,
California State University East Bay, Sutter
Health, Veterans’ Affairs Hospitals). These collaborations
not only
expand the scope of state-of-the-art expertise on projects, but
increase our capacity to readily staff projects.
Cost Effectiveness
|
 |
We
provide state-of-the-art
analyses of the economic implications of medical technologies
(pharmaceuticals, devices, and diagnostics) and services. Based on a
strong foundation in decision analyses, epidemiology, statistics, and
econometrics–combined
with more than a decade of experience working in and with life sciences
companies–we
generate analyses that are useful for a diverse array of stakeholders. |
Budget Impact
|
 |
Third-party
payers routinely
need and request high-quality evidence on
the potential fiscal implications of funding new and emerging health
technologies and services. We believe that such discussions should be
based on the foundation of "principled negotiations." Analyses to
inform these discussions require a
mutual understanding and agreement on diverse set of inputs. We have
extensive experience obtaining reliable information to such question
and developing credible fiscal forecasts. |
Strategy
|
 |
Cedar
Associates LLC assists
company decision makers–from
regulatory, clinical, commercial, and reimbursement teams–to
develop an effective strategy for commercializing a new product. Our
emphasis is primarily on the economic and reimbursement strategy, and
our experience reveals that it must be informed from input of other
teams. |
Evidence Synthesis
|
 |
We
conduct
systematic reviews
of medical literature according to the standards expected from major
stakeholders. Our staff retrieves pertinent publications and abstracts
from international congresses. We also rely on clinical and economic
experts to fill in potential gaps from using electronic databases. We
generate evidence reports that have been submitted for use in AMCP
dossiers and NICE submissions, and for reports to regulatory agencies,
clinical investigators, and senior managers. |
Statistics and
Econometric
Analysis
|
 |
Our
staff has
experience programming in SAS, STATA, S-Plus, Mathematica, and
R-statistical language. Our analyses have been published in
peer-reviewed journals, submitted to FDA, and submitted to
reimbursement agencies (CMS, UK NICE). We have experience with survival
models, ANOVA models, multivariate regression (Cox, GLM, GEE, fixed and
random effect models, logistic), time series, and Bayesian methods and
forecasting. |
|
 |
 |
 |
 |
PRESS
RELEASES
June
26, 2009
Policy analysis by John Hornberger, MD, MS, on American health care
reform was featured in the May/June 2009 issue of ISPOR connections. Read more.
May 5,
2009 Molecular Diagnostics
cites Cedar
Associate LLC's economic analysis of Genomic Health's Oncotype
DX as a "gold standard in
novel diagnostics economic analysis." Read
more.
April
23, 2009 JIAPAC
publishes Cedar manuscript coauthored by Ashwini Shewade, MS, John
Hornberger, MD, MS, and John Bartlett, MD, which proposes practical
solutions to barriers to antiretroviral treatment
in resource-limited settings. Read
more.
April 10, 2009 John
Hornberger, MD, MS, founder of Cedar, will be presenting
a session on Pharmaeconomics, Cost
Effectiveness, and Outcome Analysis for Personalized Medicine at the Drug
Information Association's 45th Annual Meeting. Read
more.
February 18, 2009
Poster coauthored by Cedar Associates Research Analyst, Julie Doberne,
on capsule endoscopy was accepted for presentation at Digestive Disease
Week. Read
more.
February 9, 2009 Cedar
presents report to Government Accounting Office (GAO) on the financial
implications of home hemodialysis. Read
more.
|
 |
 |
 |
 |
|
|
|
|
COMPANY
UPDATES
June
24, 2009
Presentations from the ISPOR Conference
and the Bio2Device Group meeting have been uploaded here.
Leona Chan, a graduate of UC Berkeley's Public Health Policy and
Management program, joins the Cedar team
with
extensive experience in both the research and reimbursement field.
April
26, 2009 Cedar
Associates LLC welcomes
Richard Hornberger, Mark Friedmann, and Tamara Love to the Cedar team.
They bring over 20 years of industry experience across such areas as
project management, business development, and administration, to
support the company's growth.
|
|
|
|
|
|
|
|
|
PAST
EVENTS
June
25, 2009
BioEconomy Summit
At the BioEconomy
Summit at Santa Clara
University in Santa Clara, California, Dr. Hornberger will be
on the panel
of Healthcare Policy Session 1: Reimbursement and Healthcare
Reform.
June
23, 2009
DIA
45th Annual Meeting
At this year's annual Drug Information Association meeting, Dr.
Hornberger will
be presenting a session on "Pharmacoeconomics, Cost Effectiveness, and
Outcome Analysis for Personalized Medicine" in San Diego, California. Click
here for press release.
June
20, 2009
ISPOR
14th Annual International
Meeting
Dr. Hornberger (Principal/Founder) is Chair of the Scientific Program
for the
13th Annual Meeting of the International Society of Pharmacoeconomic
Research
(ISPOR) to be held in Orlando, FL on May 16 to 20 (Click here for more
information). He will be moderating the session entitled "A roadmap for
knowing what works in health care: Will a US National clinical
effectiveness
center show the way?" during which a recent report recommended to the
United States Congress to establish a single national clinical
effectiveness
assessment entity will be discussed and debated.
June
20, 2009
MedImmune
Advisory Panel
Dr. Hornberger (Principal/Founder) will be serving on MedImmune's Systemic
Lupus Erythematosus Value and Health Economics Advisory
Panel, to be held
in the Washington Marriott at Metro Center.
June
9, 2009
Bio2Device
Group Health Technology Assessment (HTA) Presentation
Cedar will be presenting at the Bio2Device Group, a Silicon Valley
organization
that focuses on the convergent needs of engineers, scientists,
business,
regulatory and other biospace professionals working in the
biotechnology,
medical device, diagnostics and pharmaceutical industries.
June
2, 2009
Digestive
Disease Week
Presentation on "Evidence Quality Assessment for Use of Capsule
Endoscopy
(CE) in Suspected Small Bowel Crohn’s Disease (CD)" to be
held at the
Digestive Disease Week conference in Chicago, Illinois.
|
|
|
|
|
|
